# Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients

> **NCT01523431** · PHASE2,PHASE3 · COMPLETED · sponsor: **The Affiliated Hospital of the Chinese Academy of Military Medical Sciences** · enrollment: 583 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Irinotecan Injection [Camptosar]
- **DRUG:** 5-fluorouracil
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT01523431
- **Lead sponsor:** The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-08
- **Primary completion:** 2015-11-23
- **Final completion:** 2016-04-27
- **Target enrollment:** 583 (ACTUAL)
- **Last updated:** 2017-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01523431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01523431, "Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01523431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*